- $5.50bn
- $5.67bn
- £361.70m
- 85
- 14
- 94
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 39.03 | ||
| PEG Ratio (f) | 1.73 | ||
| EPS Growth (f) | 29.24% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.1 | ||
| Price to Tang. Book | 36.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.55 | ||
| EV to EBITDA | 73.3 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.01% | ||
| Return on Equity | 0.35% | ||
| Operating Margin | 2.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 233.2 | 259.9 | 260 | 462.9 | 361.7 | 414.05 | 453.15 | 10.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +84.8 | -15.35 | -31.45 | +5.48 | -8.74 | +70.3 | +27.69 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Abcam plc is a global life science company. The Company serves customers at the forefront of life science research through the identification, development, and distribution of biological reagents. Its products are used by researchers around the world to study biological pathways critical for scientific research, diagnostics, and drug discovery. It offers a selection of products in its catalogue to support research on proteins in biological pathways. Its principal catalogue product lines include primary and secondary antibodies, conjugated antibodies and conjugation kits, and singleplex immunoassays. It offers a range of peptides and proteins, which include cytokines, growth factors, and enzymes. It offers a range of knockout cell lines and lysates, which are used for its in-house validation needs and are also made available to its customers for their own research. It offers a variety of other products, including cellular activity kits, biochemicals and cell signaling pathway tools.
Directors
- Alan Hirzel CEO
- Michael Baldock CFO (56)
- Marc Perkins GCN
- Mark Capone NED (58)
- Sally Crawford NED (68)
- Chienling Lee NED (55)
- Mara Aspinall NID (58)
- Giles Kerr NID (61)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- February 12th, 1998
- Public Since
- January 1st, 1970
- No. of Employees
- 1,800
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 229,309,701
- Address
- Discovery Drive, CAMBRIDGE, CB20AX
- Web
- https://www.abcam.com/
- Phone
- +44 1223696000
- Auditors
- PricewaterhouseCoopers LLP
Similar to ABCM
Amgen
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
Annexon
NASDAQ Global Select Market
FAQ
As of Today at 06:00 UTC, shares in Abcam are trading at $23.99. This share price information is delayed by 15 minutes.
Shares in Abcam last closed at $23.99 and the price had moved by +48.73% over the past 365 days. In terms of relative price strength the Abcam share price has outperformed the S&P500 Index by +27.09% over the past year.
The overall consensus recommendation for Abcam is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Abcam does not currently pay a dividend.
Abcam does not currently pay a dividend.
Abcam does not currently pay a dividend.
To buy shares in Abcam you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $23.99, shares in Abcam had a market capitalisation of $5.50bn.
Here are the trading details for Abcam:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ABCM
Based on an overall assessment of its quality, value and momentum Abcam is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Abcam is $23.98. That is 0.06% below the last closing price of $23.99.
Analysts covering Abcam currently have a consensus Earnings Per Share (EPS) forecast of £0.39 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abcam. Over the past six months, its share price has outperformed the S&P500 Index by +40.94%.
As of the last closing price of $23.99, shares in Abcam were trading +20.1% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abcam PE ratio based on its reported earnings over the past 12 months is 39.03. The shares last closed at $23.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abcam's management team is headed by:
- Alan Hirzel - CEO
- Michael Baldock - CFO
- Marc Perkins - GCN
- Mark Capone - NED
- Sally Crawford - NED
- Chienling Lee - NED
- Mara Aspinall - NID
- Giles Kerr - NID